Summary
An open parallel trial with glipizide or tolbutamide was carried out in a cohort of 29 comparable maturity-onset diabetic patients. Eighteen of these individuals were studied in detail. During six months of active drug therapy the mean decrease in fasting serum glucose levels on glipizide was 25 ±2% versus 17±2% on tolbutamide (p<0.025). Decreases in post prandial glucose levels were 12.2 and 10.4%. Glucose disappearance rates (Kg) during the sixth month of treatment with both drugs increased significantly: on glipizide from 0.47±0.04%/min to 0.85±0.08%/min (p<0.005), and on tolbutamide from 0.47±0.08%/min to 0.70±0.11%/min (p<0.01). Early and late insulin release (summed increases over basal for 2–10 min and 10–60 min) during intravenous glucose tolerance testing increased during glipizide, but not during tolbutamide therapy. Post prandial insulin increments over basal during an oral glucose tolerance test also increased during glipizide, but not tolbutamide therapy. Both drugs were comparable with regard to efficacy and safety; however, only glipizide had chronic effects upon insulin secretion.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Karam JH, Matin SB, Forsham PH (1975) Antidiabetic drugs after the University Group Diabetes Program (UGDP). Annu Rev Pharmacol Toxicol 15: 351–366
Hecht A, Gershberg H, Hules M (1973) Effect of chlorpropamide treatment on insulin-secretion in diabetics-it's relationship to the hypoglycaemic effect. Metabolism 21: 723–733
Barnes AJ, Garbien KJT, Crowley MF, Bloom A (1974) Effect of short and long-term chlorpropamide treatment on insulin release and blood glucose. Lancet II: 69–72
Ohneda A, Ishii S, Horigome K, Yamagata S (1975) Glucagon response to arginine after treatment of diabetes mellitus. Diabetes 24: 811–819
Loreti L, Sugase T, Foa PO (1974) Diurnal variations of serum insulin, total glucagon, cortisol, glucose and free fatty acids in normal and in diabetic subjects before and after treatment with chlorpropamide. Horm Metab Res 5: 278–292
Olefsky JM, Reaven GM (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear cells of diabetic patients. Am J Med 60: 89–95
Boshell BR, Fox OJ, Roddam RF, Hill PS (1967) The effect of sulfonylurea agents on insulin secretion and insulin reserve. Tolbutamide. ... after ten years. Butterfield WJH, Van Westering W (ed). Exerpta Medica Found., Amsterdam, p 286–297
Herchuelz A, Malaisse WJ (1973) Insulinotropic potency of glipizide in vitro. Diabetologia 9 (Suppl): 309–310
Remein QR, Wilkerson HLC (1961) The efficacy of screening tests for diabetes. J Chronic Dis 13: 6–21
Andres R (1971) Effect of age in interpretation of glucose and tolbutamide tolerance tests. In: Fajans SS, Sussman KE (eds) Diabetes mellitus: Diagnosis and treatment. Vol 3, Chapter XX. American Diabetes Association, New York, p 115–120
Eisentraut AM, Whissen N, Unger RH (1968) Incubation damage in radioimmunoassay for human plasma glucagon and its prevention with “Trasylol”. Am J Med Sci 255: 137–142
Aguilar-Parada E, Eisentraut AM, Unger RH (1969) Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 257: 415–419
Fineberg SE, Merimee TJ (1973) Effects of comparative perfusions of equimolar, single component insulin and proinsulin in the human forearm. Diabetes 22: 676–686
Soeldner JS (1971) The intravenous glucose tolerance test. In: Fajans SS, Sussman KE (eds) Diabetes mellitus: Diagnosis and treatment. Vol 3, Chapter XIX. American Diabetes Association, New York, p 107–113
Snedecor GW, Cochran WG (1967) Statistical methods. 6th Ed. Iowa State University Press, Ames, Iowa
Ambrogi V, Bloch K, Paturi S, Griggi P, Logmen W, Parenti MA, Rabini T, Tommasin R (1971) Pharmacological study on new oral antidiabetic N-4-Beta-(5-Methyl-Pyrazine-2-Carboxyamido)-Ethyl-Benzene-Sulfonyl-N-Cyclohexyl-Urea or K4204. Arzneim Forsch 21: 208–213
Artini D, Abbiati R, Orsini G, Parenti MA, Bloch K, Daturi S, Mandelli V (1973) Pharmacodynamic aspects of 2 sulfonylurea derivatives glipizide and glibencamide. Diabetologia 9 (Suppl): 311–316
Schmidt HAE, Schoog M, Schweer KH, Winkler E (1973) Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14 glipizide, a new antidiabetic. Diabetologia 9 (Suppl): 320–330
Goldstein SM, Blecher M, Binder R, Perrino PV, Recant L (1975) Hormone receptors 5. binding of glucagon and insulin to human circulating mononuclear cells in diabetes mellitus. Endocrinol Res Commun 2: 367–376
Seltzer HS, Allen, EW, Herron Jr AL, Brennan MT (1967) Insulin secretion in response to glycemic stimulus: Relation of delayed initial insulin release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46: 323–335
Blackard WG, Nelson NC (1971) Portal and peripheral vein immunoreactive insulin concentrations in diabetic subjects. Diabetes 20: 168–170
Gerich JE, Langlois M, Naocco C, Lorenzi M, Karam JH, Forsham PH (1967) Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus. J Clin Invest 58: 320–325
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fineberg, S.E., Schneider, S.H. Glipizide versus tolbutamide, an open trial. Diabetologia 18, 49–54 (1980). https://doi.org/10.1007/BF01228302
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01228302